SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-006828 to IMAC Holdings, Inc. (BACK) (CIK 0001729944) (BACK)

IMAC Holdings, Inc. (BACK) (CIK 0001729944)
Date: June 14, 2024 · CIK: 0001729944 · Accession: 0000000000-24-006828

AI Filing Summary & Sentiment

File numbers found in text: 001-38797

Date
June 14, 2024
Author
Not clearly detected
Form
UPLOAD
Company
IMAC Holdings, Inc. (BACK) (CIK 0001729944)

Letter

United States securities and exchange commission logo June 14, 2024 Faith Zaslavsky Chief Executive Officer IMAC Holdings, Inc. 3401 Mallory Lane, Suite 100 Franklin, TN 37067 Re:IMAC Holdings, Inc. Preliminary Proxy Statement on Schedule 14A Filed June 6, 2024 File No. 001-38797 Dear Faith Zaslavsky: We have limited our review of your filing to the issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Preliminary Proxy Statement on Schedule 14A filed June 6, 2024 General 1.We note that the preliminary proxy statement relates to the solicitation of stockholder approval for the potential issuance of an excess of 19.99% of your outstanding common stock under your outstanding Series D Preferred Stock and Series E Preferred Stock, which were issued in connection with the acquisition of the assets of Theralink. Please revise the proxy statement to provide all of the information required by Item 14 of Schedule 14A. 2.Please provide the financial information required by Items 14(b)(11) and 14(c)(2) of Schedule 14A, including audited financial statements for the two most recent fiscal years for Theralink, and pro forma financial information accounting for the acquisition of the assets of Theralink. Please also provide interim unaudited financial statements, as applicable. Refer to Rules 8-04 and 8-05 and Article 11 of Regulation S-X.

FirstName LastNameFaith Zaslavsky Comapany NameIMAC Holdings, Inc. June 14, 2024 Page 2 FirstName LastName Faith Zaslavsky IMAC Holdings, Inc. June 14, 2024 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Juan Grana at 202-551-6034 or Jane Park at 202-551-7439 with any other questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Carol W. Sherman, Esq.

Show Raw Text
United States securities and exchange commission logo
June 14, 2024
Faith Zaslavsky
Chief Executive Officer
IMAC Holdings, Inc.
3401 Mallory Lane, Suite 100
Franklin, TN 37067
Re:IMAC Holdings, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed June 6, 2024
File No. 001-38797
Dear Faith Zaslavsky:
            We have limited our review of your filing to the issues we have addressed in our
comments. In some of our comments, we may ask you to provide us with information so we may
better understand your disclosure.
            Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
            After reviewing your response to this letter, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A filed June 6, 2024
General
1.We note that the preliminary proxy statement relates to the solicitation of stockholder
approval for the potential issuance of an excess of 19.99% of your outstanding common
stock under your outstanding Series D Preferred Stock and Series E Preferred Stock,
which were issued in connection with the acquisition of the assets of Theralink. Please
revise the proxy statement to provide all of the information required by
Item 14 of Schedule 14A.
2.Please provide the financial information required by Items 14(b)(11) and 14(c)(2) of
Schedule 14A, including audited financial statements for the two most recent fiscal years
for Theralink, and pro forma financial information accounting for the acquisition of the
assets of Theralink. Please also provide interim unaudited financial statements, as
applicable. Refer to Rules 8-04 and 8-05 and Article 11 of Regulation S-X.

 FirstName LastNameFaith Zaslavsky
 Comapany NameIMAC Holdings, Inc.
 June 14, 2024 Page 2
 FirstName LastName
Faith Zaslavsky
IMAC Holdings, Inc.
June 14, 2024
Page 2
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Please contact Juan Grana at 202-551-6034 or Jane Park at 202-551-7439 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Carol W. Sherman, Esq.